Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank86
3Y CAGR+6.5%
5Y CAGR-4.4%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+6.5%/yr
vs +6.7%/yr prior
5Y CAGR
-4.4%/yr
Recent acceleration
Acceleration
-0.3pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $49.01M | +11.6% |
| 2024 | $43.91M | +14.8% |
| 2023 | $38.26M | -5.8% |
| 2022 | $40.61M | -37.4% |
| 2021 | $64.85M | +5.6% |
| 2020 | $61.43M | +113.7% |
| 2019 | $28.75M | -8.1% |
| 2018 | $31.28M | +14.3% |
| 2017 | $27.36M | +13.9% |
| 2016 | $24.03M | - |